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Background: Bariatric surgery is currently restricted to those with a Body Mass Index (BMI) >40 kg/m2 or a BMI >35 kg/m2 with obesity 
related co-morbidities. However, there is a large population of class 1 obese individuals (BMIs between 30 to 35 kg/m^2) with obesity related co-
morbidities. Offering bariatric surgery to these patients may be cost-effective.
Methods: Our goal was to assess the comparative effectiveness of Laparoscopic Roux-en-Y Gastric Bypass (LARYGB) and Laparoscopic Gastric 
Band (LAGB) versus non-surgical treatment for class 1 obese patients with hypertension, diabetes, and hyperlipidemia. We created a cohort of 
46 year-old patients diagnosed with diabetes, hypertension, hyperlipidemia, and a BMI of 32.5 kg/m2. Quality Adjusted Life Years (QALYs) were 
estimated using the United Kingdom Prospective Diabetes Study (UKPDS) Computer Simulation Model. The inputs for the UKPDS model include 
HbA1c, cholesterol, systolic blood pressure, age, and weight. Inputs for the bariatric surgery treatment group were based on bariatric surgery meta-
analysis in patients with BMI >35. Bariatric surgery trials in patients with BMI <35 showed that the outcomes were the same or better than those 
reported in the meta-analysis in patients with BMI >35. Inputs for the UKPDS for the medical treatment alone arm were from UKPDS and Heart 
Protection studies. Surgery costs were derived from previous cost-effectiveness studies. Medical treatment costs were assumed to be driven by 
diabetes status.Yearly utilities and costs were discounted at a rate of 3%. A one-way sensitivity analysis was also performed.
Results: The ICER of LAGB compared to the non-surgical cohort was $9092/QALY. LARYGB was strictly dominated by LAGB in the base-case 
scenario and in the one-way sensitivity analysis of LARYGB inputs. The ICER was sensitive to changes in in BMI, HTN resolution, and cholesterol in the 
LAGB cohort.
Conclusion: Our study suggests that LAGB is more cost-effective than LARYGB and medical treatment alone in class 1 obese diabetics with 
hypertension and hyperlipidemia. Our results are sensitive to changes in BMI, hypertension, and cholesterol post surgery.
